Biological effects of a proglumide derivative as cholecystokinin antagonist in conscious dogs

Abstract In conscious dogs we studied the effects of a new cholecystokinin (CCK) antagonist (coded CR 1505) on CCK 8 -stimulated exocrine pancreatic secretion and release of pancreatic polypeptide (PP). Graded doses of CCK 8 (25–400 ng kg −1 h −1 ) were infused i.v. Experiments were repeated against a background infusion of CR 1505 at different doses (0.1, 1 and 10 mg kg −1 h −1 ). The lowest dose of CR 1505 had no biological effects. However, at the upper two doses the compound significantly inhibited the CCK 8 -stimulated PP release. Furthermore, a significant inhibition of exocrine pancreatic protein secretion was observed with 10 mg kg −1 h −1 of CR 1505 ( P